Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...

Health experts have argued that UK customers are being hoodwinked by the drug firms behind the 'useless' medicines - which include Sudafed, Lemsip and Beechams.

The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

Since 2022, the federal government has invested $26.1 million to help make naloxone, a medicine that blocks the effects of ...

ALK will initially focus on bringing neffy® to the markets in Europe and Canada, the world's second and third largest adrenaline autoinjector ("AAI”) markets. In both markets, the product can be added ...

Phenylephrine is both the most common decongestant on pharmacy shelves, and arguably the worst at its job. Last year, the FDA ...

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...